Visit https://www.peervoice.com/SSK860 to view the entire programme with slides. After completing “Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer”, participants will be able to: Describe the importance of first-line maintenance therapy for patients with advanced ovarian cancer: Differentiate among PARP inhibitors in terms of mutation status, dosing and administration, and adverse events; Formulate optimal personalised treatment plans taking into account individual- and disease-related factors for patients with advanced ovarian cancer.

Visit https://www.peervoice.com/JBJ860 to view the entire programme with slides. After completing “GP Empowerment: Eliminating HCV From the Front Line”, participants will be able to: Formulate tailored treatment plans for patients with hepatitis C virus (HCV), depending on patient and disease factors; Use patient-physician communication about HCV and its treatment as a tool to improve patient identification; Apply evidence-based therapies to optimise sustained virological response rates and patient quality of life.

Visit https://www.peervoice.com/FEW860 to view the entire programme with slides. After completing “Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?”, participants will be able to: Explain the rationale for the current focus on slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes (T2DM); Evaluate the use of GLP-1 RAs as part of a for multifactorial management plan for patients with T2DM and CKD; Formulate treatment plans incorporating current guideline recommendations to slow the progression of CKD in patients with T2DM.

Visit https://www.peervoice.com/TWY860 to view the entire programme with slides. After completing “If You Suspect, Test! The Important First Steps to Preventing the Devastating Consequences of Hepatitis”, participants will be able to: Recognise the need for routine screening for HCV/HBV infection; Apply practical strategies for HCV/HBV screening; Formulate patient-centred approaches for communicating with patients about the need for HCV/HBV screening.

Visit https://www.peervoice.com/NMW860 to view the entire programme with slides. After completing “Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy”, participants will be able to: Describe the cardiovascular adverse events that have been associated with use of proteasome inhibitors for treatment of multiple myeloma; Develop strategies to prevent and manage cardiovascular adverse events in patients with multiple myeloma.

Visit https://www.peervoice.com/VXE860 to view the entire programme with slides. After completing “Can Long-Acting Injectables Make a Difference in HIV?”, participants will be able to: Evaluate the clinical evidence for long-acting injectable therapy for people living with HIV (PLWH); Summarise the potential benefits and limitations of daily vs long-acting therapy in the long-term management of HIV; Create individualised management strategies for therapy for PLWH, taking into account patient needs.

Visit https://www.peervoice.com/RAN860 to view the entire programme with slides. After completing “Optimising Standard of Care for Patients With Axial Spondyloarthropathies: Why Gender Matters!”, participants will be able to: Recognise the differences and similarities between radiographic and non-radiographic axSpA and the need for earlier detection; Describe the unique challenges of diagnosing and treating women with axSpA; Identify patient and disease characteristics that need to be considered when selecting an appropriate long-term biologic strategy.

Visit https://www.peervoice.com/KYP860 to view the entire programme with slides. After completing “Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure”, participants will be able to: Identify the importance of reducing hepatocellular carcinoma (HCC) risk and improving secondary outcomes in patients receiving viral suppressive therapy; Recognise that antiviral suppressive therapies may differ in their impact on HCC risk and secondary outcomes; Describe the latest data for suppressive therapies and their potential impact on treatment strategies.

Visit https://www.peervoice.com/PTD860 to view the entire programme with slides. After completing “Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes”, participants will be able to: Explain the impact of hypercapnia on critically ill patients within the intensive care setting; Identify patients who would be candidates for low-flow extracorporeal carbon dioxide removal (ECCO2R); Evaluate how to appropriately integrate low-flow ECCO2R techniques in clinical practice.

Visit https://www.peervoice.com/XQB860 to view the entire programme with slides. After completing “Evolving the Treatment Paradigm in Metastatic HER2-Positive Breast Cancer: The Ongoing Story of Emerging Treatments”, participants will be able to: Summarise unmet needs in the management of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer; Explain the rationale for novel pathways and mechanism of actions for treating advanced metastatic HER2-positive breast cancer; Analyse data from clinical trials, evaluating the efficacy and safety of novel HER2-targeted therapies.